Expansion and Characterization of Iovance Marrow Infiltrating Lymphocytes: A Potential Novel Therapeutic Strategy for the Treatment of Acute Myeloid Leukemia

Conclusion: We demonstrated the feasibility of MIL expansion from bone marrow mononuclear cells from AML patients. MIL are functionally active and mostly comprised of effector memory T cells. Confirmation of tumor cell antigen specificity will determine whether MIL may deploy a robust anti-tumor activity in vivo.DisclosuresKaryampudi: Iovance Biotherapeutics: Employment, Equity Ownership. Frank: Iovance Biotherapeutics: Employment, Equity Ownership. Blaskovich: Iovance Biotherapeutics: Equity Ownership. Chartier: Iovance Biotherapeutics: Equity Ownership.

Source: Blood - November 21, 2018 Category: Hematology Authors: Karyampudi, L., Frank, I., Blaskovich, M., Byrd, J. C., Chartier, C., Long, M. Tags: 703. Adoptive Immunotherapy Source Type: research